Quarterly ResultAug 5, 2026, 07:13 AM
Q32 Bio Raises $187.6M in Follow-On Offering; H1 Net Loss $16.6M
AI Summary
Q32 Bio Inc. completed a follow-on public offering in July 2026, raising $187.6 million in net proceeds through the sale of common stock and pre-funded warrants. This significant financing bolstered the company's cash position, which stood at $106.3 million as of June 30, 2026. For the first half of 2026, the clinical-stage biotechnology company reported a net loss of $16.6 million, an improvement from the $20.5 million loss in the prior year period. The company also completed a private placement, an ATM offering, and a registered direct offering during the period, collectively raising substantial capital.
Key Highlights
- Q32 Bio raised $187.6 million net from a July 2026 follow-on offering.
- Company completed a private placement, raising $53.4 million net in May 2026.
- ATM offering generated $14.2 million gross proceeds in H1 2026.
- Registered direct offering raised $10.4 million net in February 2026.
- Net loss for H1 2026 was $16.6 million, down from $20.5 million in H1 2025.
- Cash and cash equivalents totaled $106.3 million as of June 30, 2026.
- Total stockholders' equity reached $105.9 million as of June 30, 2026.
Price Impact
More from QTTB